Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Betta Pharmaceuticals Co., Ltd. (300558.SZ)
CNY69.80
+5.30 (+8.22%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 355, Xingzhong Road 311100
Hangzhou, CN
Hangzhou, CN
CEO
Lieming Ding
Website
bettapharma.com
IPO
2016-11-09
ISIN CNE100002DD9
Description
Betta Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of oncology treatments. Among its key offerings are Icotinib hydrochloride, an orally taken epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and Ensartinib hydrochloride, an anaplastic lymphoma kinase (ALK) inhibitor, both utilized in the management of non-small-cell lung cancer. Founded in 2003, the firm is headquartered in Hangzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY69.80
+5.30 (+8.22%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15M
Beta
0.54
Float Shares
234.82M
Free Float %
55.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.24% | +9.41% | +1.42% | +14.52% | +7.18% | +12.83% | -7.53% | -6.94% | -53.38% | +108.22% | +108.22% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
69.80
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | -1 |
Quality scores
Altman Z-Score
4.42
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+24.8% ★ Q1'26: +13.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-24.0% Q1'26: +133.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.0% Q1'26: -8.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+13.6% ★ Q1'26: +28.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.4% Q1'26: +11.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.47× Q1'26: 2.13× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.04B
est: 1.04B (+0.0%)
|
1.03B
est: 1.05B (-2.0%)
|
1.22B
est: 1.23B (-0.1%)
|
1.55B
est: 1.55B (+0.2%)
|
1.87B
est: 1.96B (-4.4%)
|
2.25B
est: 2.27B (-0.9%)
|
2.38B
est: 2.35B (+1.1%)
|
2.46B
est: 2.64B (-7.1%)
|
2.89B
est: 3.04B (-4.8%)
|
3.61B
est: 3.51B (+2.8%)
|
4.40B
4.35B – 4.45B
+25.3% YoY
|
4.94B
4.84B – 5.05B
+12.4% YoY
|
5.78B
5.72B – 5.84B
+16.9% YoY
|
| EBITDA |
381.75M
est: 259.53M (+47.1%)
|
301.34M
est: 262.62M (+14.7%)
|
265.28M
est: 307.27M (-13.7%)
|
454.54M
est: 388.69M (+16.9%)
|
569.95M
est: 490.49M (+16.2%)
|
517.89M
est: 568.38M (-8.9%)
|
453.58M
est: 589.28M (-23.0%)
|
578.14M
est: 654.19M (-11.6%)
|
845.10M
est: 751.61M (+12.4%)
|
1.04B
est: 869.00M (+19.8%)
|
1.09B
1.08B – 1.10B
+25.3% YoY
|
1.22B
1.20B – 1.25B
+12.4% YoY
|
1.43B
1.42B – 1.45B
+16.9% YoY
|
| EBIT |
362.35M
est: 153.81M (+135.6%)
|
233.23M
est: 155.64M (+49.9%)
|
166.08M
est: 182.10M (-8.8%)
|
311.78M
est: 230.35M (+35.4%)
|
414.79M
est: 290.68M (+42.7%)
|
348.77M
est: 336.84M (+3.5%)
|
206.96M
est: 349.22M (-40.7%)
|
279.88M
est: 347.38M (-19.4%)
|
476.96M
est: 399.11M (+19.5%)
|
490.50M
est: 461.45M (+6.3%)
|
578.03M
571.69M – 584.36M
+25.3% YoY
|
649.78M
636.45M – 663.11M
+12.4% YoY
|
759.77M
751.44M – 768.10M
+16.9% YoY
|
| Net Income |
368.80M
est: 377.41M (-2.3%)
|
257.73M
est: 279.03M (-7.6%)
|
166.82M
est: 180.32M (-7.5%)
|
230.82M
est: 234.83M (-1.7%)
|
606.36M
est: 624.82M (-3.0%)
|
383.07M
est: 528.37M (-27.5%)
|
145.42M
est: 218.06M (-33.3%)
|
348.03M
est: 423.67M (-17.9%)
|
402.57M
est: 521.15M (-22.8%)
|
305.33M
est: 585.56M (-47.9%)
|
786.23M
771.00M – 793.29M
+34.3% YoY
|
955.12M
946.34M – 1.06B
+21.5% YoY
|
1.43B
1.40B – 1.44B
+49.6% YoY
|
| SGA |
617.97M
est: 509.05M (+21.4%)
|
525.41M
est: 515.11M (+2.0%)
|
670.49M
est: 602.67M (+11.3%)
|
819.78M
est: 762.37M (+7.5%)
|
946.77M
est: 962.04M (-1.6%)
|
1.14B
est: 1.11B (+2.4%)
|
1.23B
est: 1.16B (+6.8%)
|
1.12B
est: 1.18B (-5.8%)
|
1.36B
est: 1.36B (+0.1%)
|
1.04B
est: 1.57B (-33.9%)
|
1.97B
1.95B – 1.99B
+25.3% YoY
|
2.22B
2.17B – 2.26B
+12.4% YoY
|
2.59B
2.56B – 2.62B
+16.9% YoY
|
| EPS |
1.01
est: 0.90 (+12.2%)
|
0.64
est: 0.67 (-3.8%)
|
0.42
est: 0.43 (-2.3%)
|
0.58
est: 0.56 (+3.6%)
|
1.50
est: 1.49 (+0.7%)
|
0.92
est: 1.26 (-27.0%)
|
0.35
est: 0.52 (-32.7%)
|
0.83
est: 1.01 (-17.9%)
|
0.96
est: 1.25 (-23.0%)
|
0.73
est: 1.40 (-47.9%)
|
1.87
1.84 – 1.90
+33.6% YoY
|
2.40
2.26 – 2.54
+28.3% YoY
|
3.40
3.35 – 3.45
+41.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-14 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
625.18M
OE per share TTM
1.48
Owner's Yield
2.82%
Maintenance CapEx ratio
108.01%
Maint CapEx / Avg PPE
79.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
250.1K
Shares Outstanding
420.73M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fei Wu | Supervisor & Senior Director of Internal Control Affairs | — | male |
| Hena Shi | VP, COO & General Manager of Oncology Business Department | — | — |
| Jia Tong | CEO & Director | — | female |
| Jiang Wan | Senior VP, President of Global Sales & Director | — | male |
| Jianxun Fan | Vice President, Chief Financial Officer & Director | — | male |
| Lieming Ding | Founder, Chairman of the Board, Chief Executive Officer & GM | — | male |
| Lingxi Wu | Board Secretary & Head of Chairman Office | — | male |
| Mao Li | President of R&D, Chief Medical Officer & Director | — | — |
| Shi Zhe Ding | Director & Assistant to the Chairman | — | male |
| Weisheng Huang | Chief Chemist | — | — |
| Yangnan Zhang | Chairman of the Supervisory Board & Senior Director of Project Declaration | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300558.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
